| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Human immunodeficiency virus 1 Envelope surface glycoprotein gp120. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human immunodeficiency virus 1 (HIV1) |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | Neut; ELISA |
| Application Notes | The antibody is recommended for detection of HIV1 gp120 by Neut, ELISA assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-HIV1 gp120 Neutralizing Antibody (V3S-0522-YC7117) in Western Blot.
Western blot analysis of V3S-0522-YC7117 was performed by loading recombinant HIV-1 [HIV-1/Clade B/C (CN54)] gp120 protein, (His tag) onto a 12% Tris-HCl polyacrylamide gel. proteins were transferred to a NC membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC7117 and HRP conjugated anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 1 Anti-HIV1 gp120 Neutralizing Antibody (V3S-0522-YC7117) in Western Blot.
Figure 2 Anti-HIV1 gp120 Neutralizing Antibody (V3S-0522-YC7117) in ELISA.
ELISA analysis of V3S-0522-YC7117 was performed by coating with recombinant HIV-1 [HIV-1/Clade B/C (CN54)] gp120 protein, (His tag). Then blocked with BSA and incubated with V3S-0522-YC7117. The HRP conjugated anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 2 Anti-HIV1 gp120 Neutralizing Antibody (V3S-0522-YC7117) in ELISA.
